Clinical Trials Browser

Phase 2 × infigratinib × 90 days × Clear all

NCT04233567 2026-02-24

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Phase 2 Completed

17 enrolled 12 charts

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma